|
|
| | PAROXETINE-D4 HCL Basic information |
| Product Name: | PAROXETINE-D4 HCL | | Synonyms: | Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S,4R)- (9CI);1,3-benzodioxol-5-yl-[4-(4-fluorophenyl)-3-piperidinyl]methanol hydrochloride;PAROXETINE-D4 HCL kf-yuwen(at)kf-chem.com;Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S-trans)-;Paroxetine Hydrochloride (350 mg);Paroxetine Hydrochloride (350 mg)G0D0030.972mg/mg(ai);Paroxetine-D4 hydrochloride;PAROXETINE-D4 HCL | | CAS: | 110429-35-1 | | MF: | C19H23ClFNO4 | | MW: | 383.84 | | EINECS: | 000-000-0 | | Product Categories: | Active Pharmaceutical Ingredients;Cnbio;Serotonin | | Mol File: | 110429-35-1.mol |  |
| | PAROXETINE-D4 HCL Chemical Properties |
| Melting point | 121-131 C | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | Slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol (96 per cent) and in methylene chloride. | | form | powder | | color | white | | λmax | 292nm(H2O)(lit.) | | Merck | 14,7043 | | InChI | InChI=1/C19H20FNO3.ClH.H2O/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;;/h1-6,9,14,17,21H,7-8,10-12H2;1H;1H2/t14-,17-;;/s3 | | InChIKey | QRQSGFFISBKLMZ-BGBHMREKNA-N | | SMILES | C([C@@H]1CNCC[C@H]1C1C=CC(F)=CC=1)OC1C=CC2OCOC=2C=1.Cl.O |&1:1,6,r| | | CAS DataBase Reference | 110429-35-1 |
| | PAROXETINE-D4 HCL Usage And Synthesis |
| Chemical Properties | White or almost white, crystalline powder. | | Uses | Paroxetine Hydrochloride, is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat depression, panic attacks, obsessive-compulsive disorder (OCD), anxiety disorders, post-traumatic stress disorder, and a severe form of premenstrual syndrome (premenstrual dysphoric disorder). | | Uses | Antidepressant;5-HT uptake inhibitor | | Uses | Paroxetine hydrochloride hemihydrate has been used: as an antidepressant to study its effects on neural stem cells (NSCs) from embryonic rat hippocampus in vitro; as a CYP 2D6 inhibitor to study its effects on the in vitro?production by human recombinant CYP 2D6 of the phenolic metabolites; as an antidepressant to study its effects on the expression of pituitary adenylate cyclase activating polypeptide (PACAP), its receptors and brain-derived neurotrophic factor (BDNF) in rat primary hippocampal neurons | | General Description | Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards | | Biochem/physiol Actions | Paroxetine hydrochloride hemihydrate is one of the most potent and selective of the selective serotonin reuptake inhibitors (SSRI); antidepressant | | in vivo | Paroxetine treatment obviously attenuates the symptoms of CIA rats. Paroxetine treatment clearly prevents the histological damage of joints and alleviates T cells infiltration into synovial tissue. Paroxetine reveals a strong effect on inhibiting CX3CL1 production in synovial tissues[1]. Paroxetine (20 mg/kg/day) reduces the myocyte cross-sectional area in rat and ROS formation in the remote myocardium. Paroxetine reduces the susceptibility to ventricular tachycardia. Paroxetine treatment following MI decreases LV remodeling and susceptibility to arrhythmias, probably by reducing ROS formation[2]. In CCI paroxetine-treated group, paroxetine (10 mg/kg, i.p.) produces hyperalgesia at days 7 and 10 (P<0.01), but a decrease in pain behavior is seen at day 14. Moreover, paroxetine (10 mg/kg) significantly attenuates tactile hypersensitivity when compared to CCI vehicle-treated group[5]. |
| | PAROXETINE-D4 HCL Preparation Products And Raw materials |
|